1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1978
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologicHigh volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer
Jones R, Myers C, Guarino A, Dedrick R, Hubbard S, DeVita V. High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer. Cancer Chemotherapy And Pharmacology 1978, 1: 161-166. PMID: 373916, DOI: 10.1007/bf00253116.Peer-Reviewed Original ResearchConceptsOvarian cancerIntraperitoneal chemotherapyPhase I clinical trialAdvanced stage diseaseIntraperitoneal fluid volumeIntraperitoneal methotrexateComplete remissionTreatment modalitiesPharmacologic principlesClinical trialsPeritoneal cavityTherapeutic effectivenessChemotherapyPharmacokinetic modelingDialysis fluidToxicologic studiesCancerFluid volumeDrug distributionRational chemotherapyFurther investigationRemissionPatientsMethotrexatePharmacokineticsPharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1976
Perspectives on research in gynecologic oncology. Treatment protocols
Devita V, Wasserman T, Young R, Carter S. Perspectives on research in gynecologic oncology. Treatment protocols. Cancer 1976, 38: 509-525. PMID: 776390, DOI: 10.1002/1097-0142(197607)38:1<509::aid-cncr2820380175>3.0.co;2-a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAlkylating AgentsAntineoplastic AgentsCarcinoma, Squamous CellClinical Trials as TopicDrug EvaluationDrug Therapy, CombinationFemaleGenital Neoplasms, FemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProgestinsUterine Cervical NeoplasmsUterine NeoplasmsConceptsClinical trialsOvarian cancerAdvanced uterine cancerPostoperative adjuvant chemotherapyStage II diseaseMetastatic cervical cancerEffective adjuvant treatmentEffect of radiotherapyUse of adriamycinUse of hydroxyureaCombination of drugsL-phenylalanine mustardPathways of spreadMore effective drugsAdjuvant chemotherapyInoperable diseaseResectable tumorsAdjuvant treatmentAdvanced diseasePostoperative radiotherapySystemic chemotherapyGynecologic malignanciesSystemic treatmentTreatment failureUterine cervix